

**Amendments to the claims:**

This listing of claims will replace all prior versions, and listing, of claims in the application:

**Listing of Claims:**

Claims 16-21 (canceled).

Claim 22 (currently amended): ~~A~~ The sustained release injection formulation of claim 16, comprising

- a. one or more avermectins selected from the group consisting of abamectin, ivermectin, emamectin, eprinomectin, doramectin and moxidectin, and accounting for 0.5-30%, W/V;
- b. hydrogenated castor oil accounting for 0-10%, W/V;
- c. local analgesics accounting for 0.5-3%, W/V;
- d. BHT, BHA, PG or the combination one or more members selected from the group consisting of butylated hydroxytoluene, butylated hydroxyanisole and propyl gallate, and accounting for 0.2%, W/V; and
- e. dimethicone to the final volume.

Claim 23 (currently amended): The sustained release injection formulation of claim 16, comprising ~~22, wherein~~

- a. said one or more avermectins accounts for 1-10%, W/V;
- b. said hydrogenated castor oil accounts for 1-5%, W/V; and
- c. said trichlorobutanol accounts for 0.5%, W/V;
- d. BHT, BHA, PG 0.2%, W/V; and
- e. dimethicone with viscosity less than 100mm<sup>2</sup>/S to the final volume.

Claims 24-29 (canceled).